BFM
MAZE

Boothbay Fund Management’s Maze Therapeutics MAZE Stock Holding History

Boothbay Fund Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.64M Sell
188,857
-95,619
-34% -$2.51M 0.07% 310
2026
Q1 		$8.49M Sell
284,476
-124,896
-31% -$5.51M 0.11% 176
2025
Q4 		$17M Buy
409,372
+57,497
+16% +$1.98M 0.25% 62
2025
Q3 		$9.12M Buy
351,875
+276,345
+366% +$4.67M 0.13% 177
2025
Q2 		$927K Sell
75,530
-21,438
-22% -$223K 0.02% 706
2025
Q1 		$1.07M Buy
+96,968
New +$1.17M 0.03% 606

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Boothbay Fund Management's MAZE Position: Q2 2026 in Review

Boothbay Fund Management reduced its Maze Therapeutics (MAZE) stake by 34% in Q2 2026, selling an estimated $2.51M and leaving 188,857 shares worth $5.64M. The position accounts for 0.07% of the portfolio, ranked #310.

Boothbay Fund Management first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $17M in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Boothbay Fund Management held 188,857 shares of Maze Therapeutics worth $5.64M as of Q2 2026.
  • Boothbay Fund Management sold 95,619 Maze Therapeutics shares in Q2 2026, an estimated $2.51M.
  • Maze Therapeutics made up 0.07% of Boothbay Fund Management's portfolio in Q2 2026, its #310 holding.
  • Boothbay Fund Management first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Boothbay Fund Management's Maze Therapeutics position peaked at $17M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.